(FULC) – Globe Newswire
-
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
-
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
-
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
-
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
-
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
-
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
-
Fulcrum Therapeutics Appoints Chief Financial Officer
-
Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET
-
Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edgio, Fulcrum, adidas, and Spirit AeroSystems and Encourages Investors to Contact the Firm
-
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit
-
Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edgio, Fulcrum, adidas, and Spirit AeroSystems and Encourages Investors to Contact the Firm
-
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important June 27 Deadline in Securities Class Action – FULC
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, adidas, and Spirit and Encourages Investors to Contact the Firm
-
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Fulcrum Therapeutics, Inc. Investors to Secure Counsel Before Important June 27 Deadline in Securities Class Action – FULC
-
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, adidas, and Spirit and Encourages Investors to Contact the Firm
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
ROSEN, A LEADING NATIONAL FIRM, Encourages Fulcrum Therapeutics, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – FULC
-
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Trinseo, Edgio, and Fulcrum and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edgio, Fulcrum, and adidas and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Trinseo, Edgio, and Fulcrum and Encourages Investors to Contact the Firm
-
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Fulcrum Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FULC
-
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, adidas, and Spirit and Encourages Investors to Contact the Firm
-
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023
-
Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Edgio, Fulcrum, and adidas and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, adidas, and Spirit and Encourages Investors to Contact the Firm
-
Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET
-
FULCRUM THERAPEUTICS, INC. (NASDAQ: FULC) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fulcrum, and adidas and Encourages Investors to Contact the Firm
-
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Back to FULC Stock Lookup
